The fact that cost growth is driven largely by older products and not by new blockbuster therapies “is particularly important,” write the authors, “because in the current value-based landscape, increasing drug costs attributable to new products can sometimes be justified on the basis of improved outcomes. However, rising costs due to inflation do not reflect improved value for patients.”
The rising cost of drugs is exerting a significant strain on the US healthcare system, prompting a number of proposed policy solutions—including an international reference pricing system and mandatory price disclosure in direct-to-consumer advertising—from the current administration. Innovative drugs with high list prices, including many specialty drugs, have often been pointed to as the culprits for the increasing cost burden, but new research suggests that price hikes on older drugs are also playing a substantial role in increasing costs.
A study published this week in Health Affairs sought to address the question of how much rising drug costs are linked to inflation in the prices of existing products versus the market entry of new therapies.
The investigators obtained monthly wholesale acquisition costs for all National Drug Codes (NDCs) for all oral and injectable drugs for the years 2008 to 2016. For each year, the investigators categorized drugs as either new or existing products, and as brand-name, specialty, or generic drugs.
Between the study period, the number of NDCs in the sample grew from 11,201 to 24,825 among oral drugs and from 1708 to 3047 for injectable drugs, and the average weighted costs of products increased across the study period among all classes:
The study’s authors concluded that prices increased “considerably faster” than inflation across all drug classes, with the highest increases for oral specialty drugs. Rising costs of brand-name products were driven by inflation of prices in existing products, and rising costs among specialty products were driven by combined new product entry and existing price inflation. Finally, more expensive new generics, increasing average weighted costs.
The fact that growth is driven largely by older products and not by new blockbuster therapies “is particularly important,” write the authors, “because in the current value-based landscape, increasing drug costs attributable to new products can sometimes be justified on the basis of improved outcomes. However, rising costs due to inflation do not reflect improved value for patients.”
Reference
Hernandez I, Good CB, Cutler DM, Gellad WF, Parekh N, Shrank WH. The contribution of new product entry versus existing product inflation in the rising cost of drugs [published online January 7, 2019]. Health Aff (Millwood). doi: 10.1377/hlthaff.2018.05147.
Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab
December 6th 2023Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) in New Zealand throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in 2022.
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 27th 2023As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.